KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fulgent Genetics (FLGT) Assets (2016 - 2025)

Fulgent Genetics (FLGT) has disclosed Assets for 11 consecutive years, with $1.2 billion as the latest value for Q4 2025.

  • Quarterly Assets fell 0.53% to $1.2 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.2 billion through Dec 2025, down 0.53% year-over-year, with the annual reading at $1.2 billion for FY2025, 0.53% down from the prior year.
  • Assets hit $1.2 billion in Q4 2025 for Fulgent Genetics, roughly flat from $1.2 billion in the prior quarter.
  • In the past five years, Assets ranged from a high of $1.5 billion in Q1 2022 to a low of $999.1 million in Q1 2021.
  • Historically, Assets has averaged $1.3 billion across 5 years, with a median of $1.2 billion in 2024.
  • Biggest five-year swings in Assets: soared 1018.48% in 2021 and later dropped 10.67% in 2024.
  • Year by year, Assets stood at $1.3 billion in 2021, then grew by 1.1% to $1.3 billion in 2022, then fell by 4.45% to $1.2 billion in 2023, then decreased by 1.24% to $1.2 billion in 2024, then fell by 0.53% to $1.2 billion in 2025.
  • Business Quant data shows Assets for FLGT at $1.2 billion in Q4 2025, $1.2 billion in Q3 2025, and $1.2 billion in Q2 2025.